| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
-Melanocyte- Stimulating Hormone Analog for PET Imaging of Melanoma Metastases
1 Laboratory of Endocrinology, Department of Research, University Hospital and University Children’s Hospital, Basel, Switzerland
2 Department of Diagnostic and Therapeutic Radiology, German Cancer Research Center, Heidelberg, Germany
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
-melanocyte-stimulating hormone (-MSH; receptor name, melanocortin type 1 receptor [MC1R]), radiolabeled -MSH analogs are potential candidates for melanoma diagnosis. The aim of this study was to develop a positron emitter-labeled -MSH analog suitable for PET imaging of melanoma metastases. Methods: A short linear -MSH analog, [Nle4,Asp5,D-Phe7]--MSH4–11 (NAPamide), was newly designed and conjugated to the metal chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to enable radiometal incorporation. Compared with our previously reported DOTA--MSH analog, DOTA-MSHoct ([DOTA-ßAla3,Nle4,Asp5,D-Phe7,Lys10]--MSH3–10), the major modification lies in the conjugation of DOTA to the C-terminal end of the peptide via the 
-amino group of Lys11, as opposed to the N-terminal -amino group. After labeling with 111In, 67Ga, and the short-lived positron emitter 68Ga, DOTA-NAPamide was characterized in vitro and in vivo using the mouse melanoma B16F1cell line. Results: DOTA-NAPamide exhibited an almost 7-fold higher MC1R binding potency as compared with DOTA-MSHoct. In B16F1 melanoma-bearing mice, both 111In-DOTA-NAPamide and 67Ga-DOTA-NAPamide behaved more favorably than 111In-DOTA-MSHoct. Both radiopeptides exhibited higher tumor and lower kidney uptake leading to tumor-to-kidney ratios of the 4- to 48-h area under the curve that were 4.6 times (111In) and 7.5 times (67Ga) greater than that obtained with 111In-DOTA-MSHoct. In addition, the 4-h kidney uptake of 67Ga-DOTA-NAPamide could be reduced by 64% by coinjection of 15 mg L-lysine, without affecting tumor uptake. Skin primary melanoma as well as lung and liver melanoma metastases could be easily visualized on tissue section autoradiographs after systemic injection of 67Ga-DOTA-NAPamide. The melanoma selectivity of DOTA-NAPamide was confirmed by PET imaging studies using 68Ga-DOTA-NAPamide. Tumor uptake was found to be highest when the smallest amount of peptide was administered. Conclusion: DOTA-NAPamide labeled with either 111In or 67Ga/68Ga is in every way superior to 111In-DOTA-MSHoct in murine models of primary and metastatic melanoma, which makes it a promising agent for melanoma targeting. High-contrast images obtained in PET studies with an experimental tumor model 1 h after injection augurs well for its clinical potential as an imaging tool.
Key Words: melanoma imaging • -melanocyte-stimulating hormone • 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid • 67Ga/68Ga • PET
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
-melanocyte-stimulating hormone (-MSH) analogs for targeting MC1R on (metastatic) melanoma.
Preclinical and clinical trials based on -MSH analogs labeled with either 18F via attachment of N-succinimidyl 4-18F-fluorobenzoate or 111In after conjugation to the metal chelator diethylenetriaminepentaacetic acid (DTPA) showed that melanoma tumors can be targeted and visualized with radiolabeled -MSH (9). However, high nonspecific accumulation of these compounds in tissues such as liver (10) known to be common sites of distant melanoma metastases prevented further clinical development of DTPA--MSH compounds. More recently, -MSH analogs that incorporate 99mTc or 88Re into their 3-dimensional structures were reported to exhibit favorable properties for melanoma imaging in a mouse model (11,12). Also, we and others developed a novel class of radiolabeled -MSH analogs, consisting of either short linear (13) or rhenium-cyclized peptides (14,15) conjugated to the metal chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). These DOTA--MSH analogs are interesting candidates for various applications of melanoma targeting in nuclear oncology not only because of their good biodistribution profiles in melanoma-bearing mice after labeling with 111In but also because they carry DOTA, which can hold 2+- and 3+-charged radiometals. However, the clinical potential of -MSH analogs might be further increased if one could lower their accumulation in kidneys, which remained high despite substantial recent progress (14).
The encouraging results with DOTA--MSH analogs prompted us to develop a radiolabeled -MSH peptide suitable for PET, which offers higher sensitivity and contrast resolution than SPECT, making it possible to visualize very small metastatic lesions, including tumor deposits in regional draining lymph nodes. As the positron emitter, we selected 68Ga (half-life [t1/2], 68 min; ß+, 88%), which is produced by a 68Ge/68Ga generator available at most PET centers and is not dependent on a cyclotron. Gallium as a radiometal is of even broader interest in nuclear medicine because it is also available as 67Ga (t1/2, 78 h), which is not only a 
-emitter useful for tumor diagnosis (-camera scintigraphy, SPECT) but also an emitter of Auger (0.1–8 keV) and conversion electrons (80–90 keV), making it attractive for internal radiotherapy (16). In this study, a new DOTA--MSH analog was designed, [Nle4,Asp5,D-Phe7-Lys11(DOTA)]--MSH4–11 (DOTA-NAPamide), in which DOTA was conjugated to the C-terminal end of the peptide via the -amino group of Lys11. Compared with our previously reported DOTA-MSHoct, [DOTA-ßAla3,Nle4,Asp5,D-Phe7,Lys10]--MSH3–10 (13), DOTA-NAPamide differs mainly by (a) the position of DOTA in the peptide (C-terminal vs. N-terminal end), (b) the net charge (charge +1 vs. +2), and (c) the reintroduction of Gly at position 10 (as in native -MSH peptide, where it was shown to play some role in MC1R affinity (17)). Since tumor uptake is closely related to receptor affinity, whereas kidney clearance is known to be influenced by the charge of molecules, we expected DOTA-NAPamide to exhibit a more favorable biodistribution profile than DOTA-MSHoct, particularly with regard to the tumor-to-kidney uptake ratio. DOTA-NAPamide was labeled with 67Ga/68Ga or with 111In for direct comparison with 111In-DOTA-MSHoct and characterized in vitro and in vivo using the B16F1 mouse melanoma cell line.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
-MSH was a gift from Novartis and [Nle4,D-Phe7]--MSH (NDP-MSH) was purchased from Bachem. The -MSH analogs [ßAla3,Nle4,Asp5,D-Phe7,Lys10]--MSH3–10 (MSHoct) and [Nle4,Asp5,D-Phe7]--MSH4–11 (NAPamide) (Fig. 1) were synthesized in our laboratory using the continuous-flow technology and Fmoc (9-fluorenylmethoxycarbonyl) strategy. Conjugation of partially protected DOTA ([4,7,10-tri(carboxymethyl-tert-butyl ester)]-1,4,7,10-tetraazacyclododecane-1-acetate) to MSHoct was performed as previously described (13). NAPamide was conjugated to DOTA by adding deprotected peptide (4.5 µmol) dissolved in N,N'-diisopropylethylamine (1.5 µL)/dimethylformamide (DMF; 100 µL) to DOTA (4.5 µmol) preincubated for 10 min with 0-[7-azabenzotriazole-1-yl]-1,1,3,3-tetramethyluronium hexafluorophosphate (5.4 µmol)/DMF (300 µL). After a 1-h incubation at room temperature and precipitation of the peptide in ice-cold diethylether, deprotection of DOTA was performed by adding 3.6 mL trifluoroacetic acid (TFA), 0.2 mL thioanisole, 0.18 mL water, and 0.02 mL 1,2-ethanedithiol. After stirring for 4 h, the deprotected DOTA-peptide was precipitated with ice-cold diethylether and resuspended in 10% acetic acid before purification by reversed-phase high-performance liquid chromatography (RP-HPLC). The major peak was collected and analyzed by electrospray ionization mass spectrometry.
|
-detector (Packard) and a Spherisorb ODS2/5-µm column under the following conditions: eluent A = 0.1% TFA in water; eluent B = 0.1% TFA in acetonitrile; gradient = 0–2 min, 96% A; 2–22 min, 96%–45% A; 22–30 min, 45%–25% A; 30–32 min, 25% A; 32–34 min, 25%–96% A; flow rate, 1.0 mL/min. When necessary, the radiolabeled DOTA-peptide was purified on a small reversed-phase cartridge (Sep-Pak C18; Waters Corp.) using ethanol as solvent. The ethanol fraction containing the purified radiopeptide was evaporated under argon at 70°C. The specific activity of the radioligands was always >7.4 GBq/µmol. 68Ga labeling was performed as followed. 68Ga was obtained in 0.5 mL 0.5N HCl from a 68Ge/68Ga radionuclide generator. After addition of 1.5 µL 1 mmol/L Ga3+, the mixture was evaporated to dryness and redissolved in 500 µL acetate buffer (0.1 mol/L, pH 4.8) to which DOTA-NAPamide (5 µL, 3.2 nmol) was added. The mixture was heated for 15 min at 90°C and 68Ga-DOTA-NAPamide was purified on an RP-cartridge as described above for 67Ga/111In-labeled DOTA-peptides. More than 98% radioactivity was incorporated into DOTA-NAPamide as checked by paper chromatography (Whatman no. 1; methanol-to-water ratio, 55:45).
Iodination of NDP-MSH was performed by the chloramine-T method. NDP-MSH (3 µg) was mixed with Na125I (37 MBq; Amersham) in 50 µL phosphate-buffered saline (PBS; 0.3 mol/L, pH 7.2), followed by the addition of 10 µL chloramine-T (2 mg/mL; Merck). After incubation for 5 min, the reaction was stopped with 500 µL dithiothreitol (DTT; 20 mg/mL) and the monoiodinated peptide was purified on a syringe packed with 0.25 g Spherisorb ODS/10-µm reversed-phase silica (Phase Separations, Inc.) using a stepwise gradient of aqueous methanol containing 1% TFA. The fractions containing 125I-NDP-MSH were supplemented with DTT (1.5 mg/mL) and stored at -20°C. Before each binding experiment, an additional purification was performed by RP-HPLC.
Cell Culture
The mouse B16F1 melanoma cell line (18) was cultured in modified Eagle’s medium supplemented with 10% heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 1% nonessential amino acids, 1% vitamin solution, 50 units/mL penicillin, and 50 µg/mL streptomycin (all from GIBCO) at 37°C in a humidified atmosphere of 95% air/5% CO2. For expansion or experiments, the cells were detached with 0.02% ethylenediaminetetraacetic acid in PBS (150 mmol/L, pH 7.2–7.4).
In Vitro Binding Assay
Competitive binding experiments were performed by incubating MC1R-expressing B16F1 cells in microplates with the radioligand 125I-NDP-MSH and a series of dilutions of competitor peptides (from 1 x 10-6 to 1 x 10-12 mol/L) at 15°C for 3 h as described previously (19). Values of the inhibitory concentration yielding 50% binding (IC50) were calculated using GraphPad Prism software.
Biodistribution Experiments and Autoradiography
All animal experiments were performed in compliance with the Swiss regulation for animal treatment.
Female B6D2F1 mice (C57Bl/6 x DBA/2 F1 hybrids, breeding pairs obtained from IFFA-CREDO) were implanted subcutaneously with 0.5 million B16F1 cells to generate a primary skin melanoma. One week later, radioligand (185 kBq, except where otherwise stated), diluted in NaCl, 0.1% bovine serum albumin, pH 7.5, was injected intravenously in the lateral tail vein in a volume of 200 µL. To determine nonspecific uptake, 50 µg -MSH was coinjected with the radioligand. To reduce kidney uptake, 15 mg L-lysine (GIBCO) was coinjected with the radioligand. The animals were killed at the indicated time points; organs and tissues of interest were dissected and rinsed of excess blood, weighed, and assayed for radioactivity in a -counter. The percentage of injected dose per gram (%ID/g) was calculated for each tissue. The total counts injected per animal were calculated by extrapolation from counts of a standard taken from the injected solution for each animal.
For tissue autoradiography experiments, B6D2F1 mice with a primary or metastatic melanoma were injected with 740 kBq radioligand. Melanoma metastases were induced by intravenous injection of 2–5 x 104 B16F1 cells preincubated for 2 d with 10–100 units/mL interferon- (Pharmingen) to increase their metastatic potential. Mice were killed 4 h after radioligand injection and tissues of interest were removed and immediately fixed in isopentane cooled in nitrogen liquid. Frozen sections (100-µm thick) were cut using a Microm HM 560 microtome refrigerated at -25°C and transferred onto glass slides precooled on dry ice. The tissue sections were placed in a lyophilizator (LDC-1M; Kühner) and dried completely overnight before exposure to a Molecular Dynamics Storage Phosphor Plate for 1–2 d. The phosphor plate was scanned with a Molecular Dynamics PhosphorImager using ImageQuant to obtain digital autoradiographs that were further processed in Adobe Photoshop 5.0. After autoradiography, dehydrated tissue sections were scanned (model EU-35; Seiko Epson Corp.) and processed using Adobe Photoshop 5.0 and superimposed on the autoradiographs.
PET Studies
B6D2F1 female mice bearing a B16F1 melanoma in their right flank were injected intravenously with 68Ga-DOTA-NAPamide. After time periods ranging from 0.5 to 3 h, animals were killed and imaged with a 20-min emission and a 10-min transmission scan on a Siemens ECAT EXACT HR+ scanner (20). Images were taken in the 3-dimensional mode, corrected for scatter and attenuation and reconstructed iteratively from a 256 x 256 matrix for viewing transaxial, coronal, and sagittal slices of 2.3 mm in thickness (21). Pixel size was 1.2 mm and transaxial resolution was 4.2 mm. Subsequently, tumor and kidneys were removed, weighed, and counted for 68Ga radioactivity in a -counter.
Analysis of Data
Unless otherwise stated, results are expressed as mean ± SEM. Statistical evaluation was performed using the 1- or 2-way ANOVA test. When significant overall effects were obtained by ANOVA, multiple comparisons were made with the Bonferroni correction. P < 0.05 was considered to indicate a statistically significant difference. The area under the curve (AUC) was calculated with GraphPad Prism software for the indicated period of time, using the mean tissue uptake value at each time point.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
Receptor Binding
The MC1R binding affinity of NAPamide, MSHoct, and their DOTA conjugates were assessed by competition binding experiments with B16F1 cells. Table 1 lists the IC50 values in comparison with that of the natural ligand -MSH as control. Although both DOTA--MSH analogs displayed favorable receptor affinity (low nanomolar range), DOTA-NAPamide exhibited higher binding potency than DOTA-MSHoct (6.7-fold). It was noted that attachment of DOTA to the N- or C-terminal end of the peptide induced a comparable moderate decrease of MC1R binding affinity, demonstrating that DOTA can be conjugated to either of the 2 peptide ends without compromising receptor affinity.
|
-MSH to block the MC1R reduced the 4-h tumor uptake of 111In- or 67Ga-DOTA-NAPamide by >80%, indicating that DOTA-NAPamide is taken up by melanoma through a receptor-mediated process (not shown). Thus, DOTA-NAPamide labeled with 111In or 67Ga displayed a more favorable overall biodistribution profile than the previously reported DOTA--MSH analog, particularly regarding kidney retention.
|
|
|
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
-MSH analog suitable for PET imaging of melanoma metastases in patients. In view of the favorable characteristics of the positron emitter 68Ga, including its production from a generator and its short half-life (68 min), we focused on the development of a Ga-labeled -MSH analog. An additional advantage of gallium is that it is also available as 66Ga and 67Ga, 2 radiometals of interest in nuclear medicine. 66Ga is a cyclotron-produced positron emitter with a longer half-life than 68Ga (9.5 h), which may therefore also be suitable for PET imaging and possibly complements 68Ga when lesions in the region of the urinary tract are suspected. 67Ga is suited for tumor diagnosis and potentially for internal radiotherapy. Therefore, a Ga-labeled -MSH analog would provide a polyvalent tool for the clinical management of melanoma, including PET imaging. We selected the metal chelator DOTA to chelate gallium since it is capable of forming stable complexes with various 3+-charged radiometals (24,25), including gallium, as demonstrated by the successful development of Ga-labeled DOTA-somatostatin analogs (26,27). A newly designed DOTA--MSH analog, DOTA-NAPamide, was used as vector. The latter differs from other DOTA--MSH analogs reported so far (13–15) by the C-terminal position of DOTA. We hypothesized that the conjugation of DOTA to the C-terminal end of the peptide via the -amino group of Lys11 would favor renal excretion by neutralizing the positive charge of the -amino group in the peptide. Diminution of the positive charge of molecules was reported to be associated with a reduction in both glomerular filtration and tubular reabsorption and, thereby, kidney accumulation (28–31). Moreover, Akisawa et al. demonstrated that renal uptake of 111In-[DTPA-D-Phe1]octreotide was enhanced by substitution of D-Phe1 with Lys but was reduced when D-Phe1 was replaced by Asp, pointing out the influence of charge on kidney retention of chelator-peptide conjugates (32). In comparison with DOTA-MSHoct, a Gly residue was introduced at position 10 to lengthen the distance between the acidic DOTA molecule and the sequence 6–9 of the peptide known to be critical for receptor recognition. Additionally, a Gly residue at this position appears to increase receptor affinity (17).
Competition binding experiments with melanoma B16F1 cells revealed that DOTA-NAPamide displayed much higher MC1R binding potency than DOTA-MSHoct, indicating that the -amino group of Lys11 is suitable for DOTA coupling. This is in agreement with reported data showing that conjugation of 4-fluorobenzoate (33) or 2.3-dihydroxy-(2S)-propyl (34) to Lys11 via its -amino group did not compromise receptor affinity. In accordance with receptor binding data, tumor uptake of 111In-DOTA-NAPamide was higher than that of 111In-DOTA-MSHoct, when tested in the same melanoma-bearing mouse model. We also observed decreased kidney accumulation of 111In-DOTA-NAPamide compared with 111In-DOTA-MSHoct. To our knowledge, the amount of 111In accumulation in kidneys was the lowest reported so far with DOTA--MSH analogs (14,15). The tumor-to-kidney ratio of radioactivity uptake could be further increased by incorporating 67Ga instead of 111In; the positive influence of gallium on biodistribution profiles of DOTA peptides has already being reported (26) and might be related to differences in the coordination chemistry of metals (35). As with most radiopeptides (12,36,37), renal accumulation of 67Ga-DOTA-NAPamide could be decreased by coinjection of L-lysine without affecting tumor retention. Unexpectedly, though the positive charge of the lysine residue was neutralized in DOTA-NAPamide, the level of reduction (64%) paralleled or even exceeded that obtained with other radiopeptides in rodents (40%–52%) (12,36,37). This indicates that the residual renal accumulation of DOTA-NAPamide may very likely be further reduced in patients by coadministration of the standard cocktail of basic amino acids. The suitability of gallium-labeled DOTA-NAPamide for metastasis imaging was confirmed by tissue autoradiography. After injection of 67Ga-DOTA-NAPamide, all macroscopically detectable melanoma lesions were indeed visible on sections of liver, lung, or skin exhibiting melanotic or amelanotic melanoma tumors. This result is particularly relevant with regard to the prevalence of pulmonary and liver metastases in cutaneous melanoma patients (10). The excellent selectivity of gallium-labeled DOTA-NAPamide was also demonstrated by PET studies using 68Ga as the positron emitter. In summary, these results indicate that coupling of DOTA to Lys11, as opposed to the usual N-terminal amino acid, might improve biologic performance of -MSH analogs, particularly regarding renal clearance.
Our study on the role of the quantity of injected peptide on the tumor-to-background ratio revealed that tumor uptake was dramatically affected by the dose of peptide, whereas nontarget tissue uptakes were not or very moderately modified (kidney). A 5-fold increase in tumor uptake was observed by reducing the peptide dosage from 420 to 20 pmol, although kidney retention decreased by only 1.4-fold. This demonstrates the importance of the specific activity of the radiopeptide: The amount of administered peptide can be kept low only if the specific activity is high, resulting in a maximum tumor-to-background ratio. The dose-dependent tumor uptake of radiopeptide may explain the lower accumulation of 111In-DOTA-NAPamide (7.6 %ID/g at 4 h) in melanoma compared with that reported for a cyclic DOTA--MSH analog (111In-labeled compound 6, 17.4 %ID/g at 4 h) (14), although both peptides exhibit similar MC1R affinity. The amount of 111In-DOTA-NAPamide injected per animal was about 20 pmol—that is, almost 500-fold more than the quantity of 111In-labeled compound 6 (0.043 pmol). Ongoing studies are focusing on improving the specific activity of 111In-DOTA-NAPamide to allow administration of a lower dosage of radiopeptide. A similar investigation has been reported in rats using a radiolabeled DOTA-somatostatin analog but with somewhat different results (38). In that study, uptake in tumor as a function of the dose of injected radiopeptide followed a bell-shape curve, the highest value being observed after administration of 330 pmol. The reason for this apparent discrepancy between the 2 studies is unclear but may be related to the presence of local endogenous ligand (for example, somatostatin) which competes with the radiopeptide for binding to the targeted receptor.
|
CONCLUSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
For correspondence or reprints contact: Sylvie Froidevaux, PhD, Department of Research, Kantonsspital Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland.
E-mail: sylvie.froidevaux{at}unibas.ch
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706.This article has been cited by other articles:
|
|
 |
|
  Z. Cheng, L. Zhang, E. Graves, Z. Xiong, M. Dandekar, X. Chen, and S. S. Gambhir Small-Animal PET of Melanocortin 1 Receptor Expression Using a 18F-Labeled {alpha}-Melanocyte-Stimulating Hormone Analog J. Nucl. Med., June 1, 2007; 48(6): 987 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wei, C. Butcher, Y. Miao, F. Gallazzi, T. P. Quinn, M. J. Welch, and J. S. Lewis Synthesis and Biologic Evaluation of 64Cu-Labeled Rhenium-Cyclized {alpha}-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator J. Nucl. Med., January 1, 2007; 48(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miao, K. Benwell, and T. P. Quinn 99mTc- and 111In-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection J. Nucl. Med., January 1, 2007; 48(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Froidevaux, M. Calame-Christe, H. Tanner, and A. N. Eberle Melanoma Targeting with DOTA-{alpha}-Melanocyte-Stimulating Hormone Analogs: Structural Parameters Affecting Tumor Uptake and Kidney Uptake J. Nucl. Med., May 1, 2005; 46(5): 887 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miao, N. K. Owen, D. R. Fisher, T. J. Hoffman, and T. P. Quinn Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models J. Nucl. Med., January 1, 2005; 46(1): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Maecke, M. Hofmann, and U. Haberkorn 68Ga-Labeled Peptides in Tumor Imaging J. Nucl. Med., January 1, 2005; 46(1_suppl): 172S - 178S. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
, 111In-DOTA-MSHoct; 
, 111In-DOTA-NAPamide; 
, 67Ga-DOTA-NAPamide) were injected into melanoma-bearing mice and radioactivity accumulated in tumor and kidney was measured 4, 24, and 48 h after injection. Results are expressed as tumor AUC (left), kidney AUC (middle), and tumor-to-kidney ratios of AUC (right) (n = 8).
). Radioactivity accumulated in main tissues was measured 4 h after injection and results are expressed as percentage of uptake (%ID/g) observed after injection of 20 pmol (mean ± SEM, n = 3 or 4). *P < 0.05, 
P < 0.001 vs. 20 pmol. SI = small intestine.
